Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

VBL grants NanoCarrier Japanese rights to GBM gene therapy

November 6, 2017 10:40 PM UTC

Vascular Biogenics Ltd. (NASDAQ:VBLT) granted NanoCarrier Co. Ltd. (Tokyo:4571) exclusive rights to develop and commercialize ofranergene obadenovec (VB-111) in Japan for $15 million up front and up to $100 million in milestones, plus tiered royalties in the high teens. VBL gained $0.30 to $6.45 on Monday.

Last month, VBL reported that an independent DSMB recommended completion of the Phase III GLOBE trial of the anti-angiogenic in recurrent glioblastoma based on a safety review. The company expects top-line data next quarter. A spokesperson told BioCentury VB-111 could be on the market in 2H19...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article